Rezdiffra Pregnancy and Lactation Registry

Part of paid clinical trials in West Conshohocken, Pennsylvania.

Sponsor
Madrigal Pharmaceuticals, Inc.
Study ID
NCT07541469
Status
Recruiting
Apply to this trial

Conditions

  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Eligibility Criteria

Sex
FEMALE
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

  • Rezdiffra — DRUG
    Exposure to at least one dose of Resmetirom.

Study Details

To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.

Key Dates

Start date
Mar 4, 2026
Status verified
Mar 2026
Primary completion
Apr 8, 2030
Completion
Apr 8, 2030

Study Design

Enrollment
10 participants (estimated)

Primary Outcome Measure

Pregnancy and Infant Outcomes Among Women Exposed to Rezdiffra During Pregnancy and/or Lactation [ Time Frame: From enrollment through pregnancy and up to 12 months of infant age (participant observational period up to approximately 21 months) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Madrigal PharmaceuticalsWest ConshohockenPennsylvania19428
Event Reporting Desk
[email protected]
1-800-905-0324

Find similar trials in West Conshohocken, PA

By research site
Madrigal Pharmaceuticals· West Conshohocken, PA

Related Studies